{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:45:49Z","timestamp":1793166349201,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.ctrv.2007.12.001","type":"journal-article","created":{"date-parts":[[2008,3,6]],"date-time":"2008-03-06T18:43:54Z","timestamp":1204829034000},"page":"193-205","source":"Crossref","is-referenced-by-count":771,"title":["Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review"],"prefix":"10.1016","volume":"34","author":[{"given":"Kiran","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim Z.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mason W.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudie","family":"Charbonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2007.12.001_bib1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","article-title":"Cancer statistics 2006","volume":"56","author":"Jemal","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2007.12.001_bib2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00345-004-0466-0","article-title":"Novel approaches in the therapy of metastatic renal cell carcinoma","volume":"23","author":"Lam","year":"2005","journal-title":"World J Urol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00345-004-0468-y","article-title":"Combination of surgery and immunotherapy in metastatic renal cell carcinoma","volume":"23","author":"Mickisch","year":"2005","journal-title":"World J Urol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJM199609193351207","article-title":"Renal-cell carcinoma","volume":"335","author":"Motzer","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2007.12.001_bib5","unstructured":"National Comprehensive Cancer Network (NCCN). Practice guidelines in oncology: kidney cancer (v.1.2007). http:\/\/www.nccn.org\/professionals\/physician%5Fgls\/PDF\/kidney.pdf (accessed October 2006)."},{"key":"10.1016\/j.ctrv.2007.12.001_bib6","unstructured":"American Cancer Society. Cancer facts and figures; 2006. http:\/\/www.cancer.org\/downloads\/STT\/CAFF2006PWSecured.pdf (accessed October 2006)."},{"key":"10.1016\/j.ctrv.2007.12.001_bib7","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(98)01041-1","article-title":"Kidney cancer","volume":"352","author":"Vogelzang","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2007.12.001_bib8","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1001\/jama.281.17.1628","article-title":"Rising incidence of renal cell cancer in the United States","volume":"281","author":"Chow","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2007.12.001_bib9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-5347(05)65382-7","article-title":"Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data","volume":"167","author":"Hock","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib10","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/jnci\/djj362","article-title":"Rising incidence of small renal masses: a need to reassess treatment effect","volume":"98","author":"Hollingsworth","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2007.12.001_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0090-4295(97)00506-2","article-title":"Increased incidence of serendipitously discovered renal cell carcinoma","volume":"51","author":"Jayson","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.ctrv.2007.12.001_bib12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/145749690409300202","article-title":"Epidemiology of renal cell carcinoma","volume":"93","author":"Lindblad","year":"2004","journal-title":"Scand J Surg"},{"key":"10.1016\/j.ctrv.2007.12.001_bib13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/01.mou.0000135078.04721.f5","article-title":"Renal cell carcinoma: etiology, incidence and epidemiology","volume":"14","author":"Murai","year":"2004","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00001622-200405000-00010","article-title":"Renal cell carcinoma","volume":"16","author":"Rathmell","year":"2004","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.cco.0000155007.51495.d6","article-title":"Renal cell carcinoma","volume":"17","author":"Rathmell","year":"2005","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/01.cco.0000219260.60714.c4","article-title":"Renal cell carcinoma","volume":"18","author":"Rini","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib17","doi-asserted-by":"crossref","unstructured":"Wallen E, Pruthi R. The burden of kidney cancer in America: the urologic diseases in America Project. In: Paper presented at: American Urological Association Annual Meeting 2006; abstract 226; May 20\u201325; 2006.","DOI":"10.1016\/S0022-5347(18)32493-5"},{"key":"10.1016\/j.ctrv.2007.12.001_bib18","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/bjc.1998.248","article-title":"Hypertension, obesity and their medications in relation to renal cell carcinoma","volume":"77","author":"Yuan","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2007.12.001_bib19","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.1200\/JCO.2005.01.8234","article-title":"Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib20","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1586\/14737140.2.6.681","article-title":"Multimodality treatment of metastatic renal cell carcinoma","volume":"2","author":"Mickisch","year":"2002","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ctrv.2007.12.001_bib21","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1002\/cncr.21453","article-title":"Targeted agents for the treatment of advanced renal cell carcinoma","volume":"104","author":"Stadler","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2007.12.001_bib22","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1056\/NEJM200009143431101","article-title":"Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation","volume":"343","author":"Childs","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2007.12.001_bib23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ccr.2004.09.006","article-title":"Focus on kidney cancer","volume":"6","author":"Linehan","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2007.12.001_bib24","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0022-5347(05)67889-5","article-title":"Systemic therapy for renal cell carcinoma","volume":"163","author":"Motzer","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib25","unstructured":"Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975\u20132004, National Cancer Institute. http:\/\/seer.cancer.gov\/csr\/1975_2004\/, (accessed November 2007)."},{"key":"10.1016\/j.ctrv.2007.12.001_bib26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1477-7525-4-68","article-title":"A brief symptom index for advanced renal cell carcinoma","volume":"4","author":"Eton","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ctrv.2007.12.001_bib27","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000049783","article-title":"Guidelines on renal cell cancer","volume":"40","author":"Mickisch","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib28","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1200\/JCO.2000.18.16.2972","article-title":"Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma","volume":"18","author":"Motzer","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib30","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H","article-title":"Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2","volume":"80","author":"Bukowski","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2007.12.001_bib31","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ncpuro0581","article-title":"Treatment for renal cancer: are we beyond the cytokine era?","volume":"3","author":"Ramsey","year":"2006","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib32","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1200\/JCO.1994.12.8.1572","article-title":"Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report","volume":"12","author":"Yang","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib33","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2003.02.122","article-title":"Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer","volume":"21","author":"Yang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib34","unstructured":"Avastin package Insert 2006. Genentech, SF, CA. http:\/\/www.gene.com\/gene\/products\/information\/oncology\/avastin\/insert.jsp, (accessed February 2007)."},{"key":"10.1016\/j.ctrv.2007.12.001_bib35","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2007.12.001_bib36","unstructured":"Nexavar(R) Package Insert, 2006. Bayer Healthcare Corporation, Leverkusen, Germany. http:\/\/www.univgraph.com\/bayer\/inserts\/nexavar.pdf, (accessed February 2007)."},{"key":"10.1016\/j.ctrv.2007.12.001_bib37","unstructured":"Sutent(R) Package Insert 2007. Pfizer inc. New York, NY. http:\/\/www.pfizer.com\/pfizer\/download\/uspi_sutent.pdf, (accessed December 2006)."},{"key":"10.1016\/j.ctrv.2007.12.001_bib38","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2007.12.001_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2005.03.7234","article-title":"Treatment options in metastatic renal carcinoma: an embarrassment of riches","volume":"24","author":"Vogelzang","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2007.12.001_bib41","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2007.12.001_bib42","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJM200112063452317","article-title":"Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma","volume":"345","author":"Pantuck","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2007.12.001_bib43","unstructured":"International Agency for Research on Cancer (IARC). GLOBOCAN database 2002. http:\/\/www-dep.iarc.fr, (accessed July 2006)."},{"key":"10.1016\/j.ctrv.2007.12.001_bib44","unstructured":"Zbrozek AS, Gilden DM, Kubisiak J, Lee A. Burden of illness study of lung, pancreatic, and renal cell cancers. In: Paper presented at: ASCO annual meeting proceedings 2002; abstract 2592; 2002."},{"key":"10.1016\/j.ctrv.2007.12.001_bib45","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.2000.18.9.1928","article-title":"Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma","volume":"18","author":"Motzer","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib46","unstructured":"Ries L, Eisner M, Kosary C, et al. SEER Cancer Statistics Review, 1975\u20132002, National Cancer Institute. http:\/\/seer.cancer.gov\/csr\/1975_2002\/, (accessed November 2006)."},{"key":"10.1016\/j.ctrv.2007.12.001_bib47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev.publhealth.22.1.91","article-title":"The burden of illness of cancer: economic cost and quality of life","volume":"22","author":"Brown","year":"2001","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.ctrv.2007.12.001_bib48","unstructured":"U.S. Bureau of labor Statistics., Division of Consumer Price Indexes. Consumer Price Indexes (CPI). http:\/\/www.bls.gov\/cpi\/home.htm, (accessed February 2007)."},{"key":"10.1016\/j.ctrv.2007.12.001_bib49","doi-asserted-by":"crossref","unstructured":"Allareddy V, Konety BR. Inpatient costs for bladder, kidney, and prostate cancers in the year 2002. A study using the NIS sample. In: Paper presented at: American Urological Association Annual Meeting, May 20\u201325; 2006; Atlanta, Georgia. abstract 232.","DOI":"10.1016\/S0022-5347(18)32499-6"},{"key":"10.1016\/j.ctrv.2007.12.001_bib50","doi-asserted-by":"crossref","unstructured":"Lang K, Danchenko N, Gondek K, Schwartz B, Thompson D. Burden of illness analysis of renal cell carcinoma. In: Paper presented at: ASCO Annual Meeting Proceedings 2006; abstract 14548; 2006.","DOI":"10.1200\/jco.2006.24.18_suppl.14548"},{"key":"10.1016\/j.ctrv.2007.12.001_bib51","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1089\/10799900050116381","article-title":"Combined treatment with low-dose interferon plus vinblastine is associated with less toxicity than conventional interferon monotherapy in patients with metastatic renal cell carcinoma","volume":"20","author":"Tsavaris","year":"2000","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.ctrv.2007.12.001_bib52","unstructured":"ISPOR. Health Care Cost, Quality, and Outcomes: ISPOR Book of Terms. Lawrenceville, New Jersey: International Society for Pharmacoeconomics and Outcomes Research; 2003."},{"key":"10.1016\/j.ctrv.2007.12.001_bib53","doi-asserted-by":"crossref","unstructured":"Gao X, Reddy P, Dhanda R, et al. Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma. In: Paper presented at: ASCO Annual Meeting Proceedings Part I 2006; abstract 4604; 2006.","DOI":"10.1200\/jco.2006.24.18_suppl.4604"},{"key":"10.1016\/j.ctrv.2007.12.001_bib54","series-title":"Cost effectiveness in health and medicine","year":"1996"},{"key":"10.1016\/j.ctrv.2007.12.001_bib55","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1634\/theoncologist.11-2-90","article-title":"Do oncologists believe new cancer drugs offer good value?","volume":"11","author":"Nadler","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2007.12.001_bib56","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00001648-199007000-00012","article-title":"Years of potential life lost (YPLL)\u2013what does it measure?","volume":"1","author":"Gardner","year":"1990","journal-title":"Epidemiology"},{"key":"10.1016\/j.ctrv.2007.12.001_bib57","unstructured":"BC Cancer Agency. BC Cancer Statistics: Potential Years of Life Lost. http:\/\/www.bccancer.bc.ca\/HPI\/CancerStatistics\/FF\/LifeLost.htm, (accessed November 2006)."},{"key":"10.1016\/j.ctrv.2007.12.001_bib58","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.bjc.6602321","article-title":"Years of life lost (YLL) from cancer is an important measure of population burden \u2013 and should be considered when allocating research funds","volume":"92","author":"Burnet","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2007.12.001_bib59","unstructured":"National Cancer Institute. SEER Cancer Statistics Review 1975\u20132000. http:\/\/seer.cancer.gov\/csr\/1975_2000\/results_merged\/topic_year_lost.pdf, (accessed November 2006)."},{"key":"10.1016\/j.ctrv.2007.12.001_bib60","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev.publhealth.22.1.91","article-title":"The burden of illness of cancer: economic cost and quality of life","volume":"22","author":"Brown","year":"2001","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.ctrv.2007.12.001_bib61","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0022-5347(01)64807-9","article-title":"Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study","volume":"157","author":"Litwin","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib62","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/pon.635","article-title":"Psychosocial and demographic predictors of quality of life in a large sample of cancer patients","volume":"12","author":"Parker","year":"2003","journal-title":"Psycho-Oncology"},{"key":"10.1016\/j.ctrv.2007.12.001_bib63","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.1996.14.2.671","article-title":"Outcomes of cancer treatment for technology assessment and cancer treatment guidelines","volume":"14","author":"American Society of Clinical Oncology","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib64","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/sj.bjc.6600996","article-title":"Rapid deterioration in quality of life during interleukin-2- and alpha-interferon-based home therapy of renal cell carcinoma is associated with a good outcome","volume":"89","author":"Atzpodien","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2007.12.001_bib65","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1200\/JCO.1999.17.11.3612","article-title":"Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy","volume":"17","author":"Heinzer","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib66","first-page":"1553","article-title":"Life quality of patients with metastatic renal cell carcinoma and chemo-immunotherapy \u2013 a pilot study","volume":"19","author":"Kroger","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2007.12.001_bib67","unstructured":"Beaumont J, Cella D, Li J, et al. Patient-Reported Fatigue in Three Sunitinib Malate (SU11248) Phase II Trials for the Treatment of Advanced Renal Cell Carcinoma, Gastrointestinal Stromal Tumor, and Neuroendocrine Tumor. In: Paper presented at: First Annual Chicago Supportive Oncology Conference 2005 Scientific Posters, October 6\u20138; 2005; Hotel InterContinental, Chicago, Illinois."},{"key":"10.1016\/j.ctrv.2007.12.001_bib68","unstructured":"Beaumont JL, Cella D, Li JZ, et al. Efficacy and patient-reported outcomes of sunitinib malate (SU11248) in three phase II trials in advanced renal cell carcinoma, gastrointestinal stromal tumor, and neuroendocrine tumor. In: Paper presented at: International Congress on Anti Cancer Treatment (ICACT); January 2006; Paris."},{"key":"10.1016\/j.ctrv.2007.12.001_bib69","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1359-6349(05)81089-4","article-title":"Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)","volume":"3","author":"Escudier","year":"2005","journal-title":"Eur J Cancer Suppl"},{"key":"10.1016\/j.ctrv.2007.12.001_bib70","doi-asserted-by":"crossref","unstructured":"Dhanda R, Gondek K, Song J, Cella D, Bukowski RM, Escudier B.A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo. In: Paper presented at: J Clin Oncol (Meeting Abstracts) 2006; 24: Abstract 4534; 2006.","DOI":"10.1200\/jco.2006.24.18_suppl.4534"},{"key":"10.1016\/j.ctrv.2007.12.001_bib71","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/S0022-5347(05)65640-6","article-title":"The changing natural history of renal cell carcinoma","volume":"166","author":"Pantuck","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib72","first-page":"20","article-title":"Cost-effectiveness and reimbursement issues in renal cell carcinoma","volume":"16","author":"Gilewski","year":"1989","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib73","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s00520-003-0484-2","article-title":"Quality of life aspects in kidney cancer patients: data from a national registry","volume":"11","author":"Anastasiadis","year":"2003","journal-title":"Supportive Care in Cancer"},{"key":"10.1016\/j.ctrv.2007.12.001_bib74","unstructured":"Bacik J, Fairclough D, Murphy B, et al. Quality of Life (QOL) Analysis for a Randomized Phase III Trial of Interferon Alfa-2a (IFN) versus IFN Plus 13-Cis-Retinoic Acid (CRA) in Patients (Pts) with Advanced Renal Cell Carcinoma (RCC). In: Paper presented at: ASCO Annual meeting Proceeding 2000; abstract 1377; 2000."},{"key":"10.1016\/j.ctrv.2007.12.001_bib75","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/1097-0142(20010515)91:10<1949::AID-CNCR1218>3.0.CO;2-A","article-title":"The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a Phase I cancer clinical trial","volume":"91","author":"Cohen","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2007.12.001_bib76","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/pon.656","article-title":"The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment","volume":"12","author":"Devine","year":"2003","journal-title":"Psychooncology"},{"key":"10.1016\/j.ctrv.2007.12.001_bib77","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1078-1439(01)00182-X","article-title":"Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine","volume":"7","author":"Cohen","year":"2002","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib78","unstructured":"Cole BF, McDermott D, Parker R, et al. The impact of treatment with high-dose interleukin-2 (HD IL-2) or subcutaneous (SC) IL-2\/interferon alfa-2b (IFN) on quality of life (QOL) in patients with metastatic renal cell carcinoma (mRCC). In: Paper presented at: ASCO Annual Meeting Proceedings 2003; abstract 1555; 2003."},{"key":"10.1016\/j.ctrv.2007.12.001_bib79","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1046\/j.1464-410X.1996.09573.x","article-title":"A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation","volume":"77","author":"Joffe","year":"1996","journal-title":"Br J Urol"},{"key":"10.1016\/j.ctrv.2007.12.001_bib80","doi-asserted-by":"crossref","unstructured":"Kondagunta G, Bacik J, Ishill N, et al. Pegylated interferon alpha-2B (PEG-Intron) for metastatic renal cell cancer (mRCC): Results of a phase II clinical trial and biologic correlates of response. In: Paper presented at: ASCO Annual Meeting Proceedings 2006; abstract 4528; 2006.","DOI":"10.1200\/jco.2006.24.18_suppl.4528"},{"key":"10.1016\/j.ctrv.2007.12.001_bib81","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/cncr.21410","article-title":"A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma","volume":"104","author":"Lee","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2007.12.001_bib82","unstructured":"Phan G, Morton K, Liewehr D, Steinberg S, Rosenberg S, Yang J. Quality of life in patients with metastatic renal cell cancer receiving different regimens of interleukin-2. In: Paper presented at: ASCO Annual Meeting Proceedings 2002; abstract 95; 2002."},{"key":"10.1016\/j.ctrv.2007.12.001_bib83","unstructured":"Plasse T, Goss T, Dutcher J, et al. Quality of life assessment of renal cancer patients treated with interleukin-2, interferon-[alpha] and 5-fluorouracil. In: Paper presented at: ASCO Annual Meeting Proceedings 1998; abstract 260; 1998."},{"key":"10.1016\/j.ctrv.2007.12.001_bib84","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/sj.bjc.6600934","article-title":"IPM chemotherapy in cytokine refractory renal cell cancer","volume":"88","author":"Shamash","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2007.12.001_bib85","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1046\/j.1444-0903.2001.00184.x","article-title":"Alpha-interferon 2a and 1 3-cis-retinoic acid for the treatment of metastatic renal cell carcinoma","volume":"32","author":"Wong","year":"2002","journal-title":"Int Med J"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737207001879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737207001879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T14:25:56Z","timestamp":1588429556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737207001879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0305737207001879"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2007.12.001","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}